Rovax 10/160 mg Tablet
Rosuvastatin Calcium 10.4mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
MFDS item code 202006067 · Approved 2020.08.28
This product's status changed to Expired on 2025.08.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of dyslipidemia; treatment of hypertension and heart failure; inhibition of atherosclerosis and cardiovascular risk
This medication is used for patients who need to take two components, Valsartan and Rosuvastatin, together. Valsartan is effective primarily for essential hypertension, heart failure, and reducing the risk of death after myocardial infarction. It is especially suitable for heart failure patients with side effects from ACE inhibitors. Rosuvastatin helps improve hypercholesterolemia and dyslipidemia and is used as an adjunct when dietary management is insufficient. Additionally, it contributes to lowering the risk of cardiovascular diseases, reducing the risk of stroke, myocardial infarction, and recurrence after vascular revascularization. Therefore, this medication is used to improve cardiovascular health in patients with both hypertension and hyperlipidemia.
This medicine is administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, valsartan and rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose of valsartan is 80 mg orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily, or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Initiate treatment with this medicine at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with this medicine at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with this medicine at 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with this medicine at 40 mg once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Over the following weeks, the dose may be increased, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or greater. However, this medicine should not be administered to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a combination product with the same amounts of each active ingredient) for convenience.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus during pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant and breastfeeding women should not take this medication and should use appropriate contraceptive methods. Patients with severely impaired liver or kidney function, muscle diseases, or certain liver diseases should not take this medication due to potential risks. Caution is advised for elderly patients, patients with hyperkalemia, and those with liver impairment, who should undergo regular liver function tests and kidney function tests. This medication can cause muscle-related adverse reactions, such as muscle pain, myopathy, and rarely rhabdomyolysis; if symptoms like muscle pain or weakness occur, consult a doctor immediately. Blood pressure may drop sharply, leading to dizziness or fainting; therefore, start at a low dose and monitor the condition. This medication can affect liver and kidney function; thus, patients with impaired function of these organs must consult a physician before taking it. There may be interactions when taken with other drugs, so if you are taking other medications, you must inform your doctor, especially caution is needed when used in conjunction with potassium-sparing diuretics, potassium supplements, certain antibiotics, antifungals, immunosuppressants, etc. It is advisable to avoid or limit alcohol intake during the use of this medication, and if signs of liver dysfunction occur, contact a physician immediately. The safety and effectiveness in children and adolescents have not been established, so it is generally not recommended for this age group. There is no specific antidote for overdose, and immediate medical attention is required for appropriate treatment, as hypotension or altered consciousness may occur. Store this medication out of the reach of children, and be careful not to transfer it to another container.
Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial swelling, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver aminotransferases (AST, ALT), increased serum creatine phosphokinase, increased serum potassium, elevated gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory loss, anxiety, upper respiratory infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral hemorrhage, vomiting, insulin-dependent diabetes mellitus, diabetic complications, leg fractures, spinal fractures, fractures, skin mass, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unspecified skin neoplasm-like condition, shingles, herniated disc, hemoptysis, sputum disease, bronchitis, sensory abnormalities, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, elevated triglycerides, increased blood pressure, worsening hypertension, neck/shoulder pain, toe fractures, osteomyelitis, skin infections, unspecified dermatitis, localized skin reactions, palpitations, worsening angina, auditory disturbances, overactive bladder, increased serum creatinine, prostate enlargement, laceration, headache, dizziness, viral infection, upper respiratory infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, abdominal discomfort, pharyngitis, arthralgia, hypotension, orthostatic dizziness, orthostatic hypotension, kidney function impairment, hyperkalemia, drowsiness, atrial fibrillation, loss of appetite, fatigue, vascular edema, erythema, pruritus, serum sickness, vasculitis, hepatitis, syncope, nasal bleeding, interstitial pneumonia, hypoglycemia, shock, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, reduction in red blood cell volume, decrease in hemoglobin, edema, constipation, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, weakness, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, jaundice, Stevens-Johnson syndrome, eosinophilia with systemic symptoms associated drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a container that blocks light and air, and the storage temperature should be maintained between 1 and 30 degrees Celsius at room temperature. Proper storage will help maintain the effectiveness and safety of the medication.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP) x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Rosuvastatin Calcium 10.4mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Rosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Medika Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.